Vutrisiran May Stabilize Right Ventricle Function in ATTR-CM

Alnylam Pharmaceuticals' stock fell 4.9% pre-market as negative data from a competitor's trial raised concerns about its RNA-silencing drug class. Wells Fargo cut its price target to $256. The company also faces competitive pressure and lowered its 2026 revenue guidance in July.

Alnylam Pharmaceuticals (ALNY) shares dropped 6% after AstraZeneca's Phase 3 trial for a silencer drug targeting ATTR-CM failed, showing no improvement in patients already on stabilizer drugs. The results raise concerns about silencer drugs in the competitive ATTR-CM treatment market, which is expected to be worth billions.

AstraZeneca's Phase 3 trial for a heart disease drug (a silencer) failed, showing no benefit for patients already on stabilizers. The study involved ATTR-CM patients and was conducted with Ionis Pharmaceuticals. The results may impact other companies like Alnylam and BridgeBio, which also market ATTR-CM drugs.

Moderna is raising $2 billion in convertible debt following the success of its personalized cancer vaccine developed with Merck. The vaccine uses an algorithm to analyze tumor mutations and create a bespoke mRNA treatment. Some investors question the necessity of personalization. Meanwhile, a U.S. biotech crackdown on China could benefit European companies, and a rival drug failure may impact Alnylam's ATTR-CM franchise.

Moderna (MRNA) shares fell 7.7% premarket after a 177% surge following positive trial results for its mRNA cancer vaccine. Five biotech stocks with imminent FDA catalysts are highlighted: Regeneron (REGN), Ultragenyx (RARE), Alnylam (ALNY), Merck (MRK), and Ionis (IONS). Each has recent approvals, upcoming data presentations, or earnings events that could impact their stock prices. Financial metrics and analyst targets are provided for each company. Bitcoin hit $72k after Trump's crypto legislat

Alnylam Pharmaceuticals (ALNY) cut its full-year 2026 TTR product sales guidance by about $200 million, citing normalized growth, and is also facing a securities law investigation. The stock fell 19.25% over 30 days and 43.24% year to date. Simply Wall St’s “undervalued” narrative sets a fair value of $434.72 versus $227.12 last close.